Introduction:
Leading pharmaceutical company has reported strong Q3FY25 results, achieving a 57% YoY revenue growth to ₹74 crore and a significant 183% increase in operating EBITDA. Net profit saw a robust 188% growth, reflecting effective cost management and strategic focus.
Also Read: Stocks To Watch For Budget 2025
Share price movement of Jagsonpal Pharmaceuticals:
On January 23, 2025, Jagsonpal Pharmaceuticals Ltd opened at ₹245.70, up 7.57% from its previous close of ₹228.35. The stock reached a high of ₹252.00 (6.46%) and a low of ₹238.20. By 10:30 AM, it traded at ₹243.10, a 6.46% increase, with a market cap of ₹1,613.33 crore.
Jagsonpal Pharmaceuticals Reports Strong Q3FY25 Growth:
Jagsonpal Pharmaceuticals reported a strong performance in Q3FY25 with a 57% YoY revenue growth to ₹74 crore. The company achieved an operating EBITDA of ₹17.1 crore, marking a significant 183% increase, and an EBITDA margin of 23.1%.
The company’s effective cost control is evident, with ESOP costs declining by 52% to ₹1.3 crore. Business PAT saw a robust 188% growth, reaching ₹11.5 crore compared to ₹4 crore in Q3FY24, reflecting improved profitability and operational efficiency.
For the nine months of FY25, Jagsonpal’s revenue increased by 27% to ₹210.2 crore, with operating EBITDA rising 53% to ₹48.2 crore. The company remains focused on sustainable growth and strategic investments for future expansion.
Stock performance of Jagsonpal Pharmaceuticals for Period of 1 week, 6 months and 1 year:
Over the past week, Jagsonpal Pharmaceuticals Ltd. has delivered a return of 2.38%. The company’s performance over the last six months and one year has been impressive, with returns of 44.5% and 52.1%, reflecting strong growth.
Also Read: Best Sectors To Watch For Budget 2025
Shareholding pattern of Jagsonpal Pharmaceuticals:
All values in % | Dec 2024 | Sep 2024 | Jun 2024 |
Promoter | 67.80% | 68.00% | 68.00% |
FII | 2.10% | 2.30% | 1.10% |
DII | 0.00% | 0.10% | 0.80% |
Public | 30.10% | 30% | 30% |
About Jagsonpal Pharmaceuticals:
Jagsonpal Pharmaceuticals Limited (NSE: JAGSNPHARM) is a leading Indian pharmaceutical company with over four decades of experience. It boasts a strong portfolio in Gynaecology, Orthopaedics, Dermatology, and Child-care, with 20+ market-leading brands and a nationwide presence.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.